Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 16/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | GPR183 | P32249 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | CASR | P41180 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1713455 | 1.00 | GPR119 (0.40) | GPR119KCNH2GPR183ACACBGABRA5 | |
| SCHEMBL1713324 | 0.89 | GPR119 (0.40) | GPR119KCNH2GPR183ACACBGABRA5 | |
| SCHEMBL1713322 | 0.89 | GPR119 (0.40) | GPR119KCNH2GPR183ACACBGABRA5 | |
| SCHEMBL1713423 | 0.88 | GPR119 (0.46) | GPR119KCNH2GPR183GABRA5 | |
| SCHEMBL1723719 | 0.88 | GPR119 (0.44) | GPR119KCNH2GPR183ACACB | |
| SCHEMBL1723723 | 0.88 | GPR119 (0.44) | GPR119KCNH2GPR183ACACB | |
| SCHEMBL1713330 | 0.87 | GPR119 (0.43) | GPR119KCNH2GPR183ACACB | |
| SCHEMBL1713337 | 0.87 | GPR119 (0.43) | GPR119KCNH2GPR183ACACB | |
| SCHEMBL2570043 | 0.82 | GPR119 (0.42) | GPR119KCNH2GPR183ACACB | |
| SCHEMBL1713600 | 0.80 | GPR119 (0.47) | GPR119KCNH2GPR183 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114935-B1 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2011-07-20 | — | — | EP | claimed |
| US-20100105732-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-04-29 | — | — | US | claimed |
| EP-2377864-A1 | Piperidine GPCR agonists | Prosidion Limited (GB) | 2011-10-19 | — | — | EP | disclosed |
| EP-2114935-B1 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2011-07-20 | — | — | EP | disclosed |
| US-20100105732-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105732-A1 | PIPERIDINE GPCR AGONISTS | GPR119, GPR27, GLP1R | GPR119 1/4885KCNH2 1128/4885GPR183 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.